Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group nucleosomal binding domain 2 pseudogene 19 (HMGN2P19) is a human genetic locus categorized as a pseudogene, meaning it is a genomic DNA sequence similar to the functional high mobility group nucleosomal binding domain 2 (HMGN2) gene but incapable of producing a functional protein product due to disabling mutations or loss of regulatory elements[1][2][5]. Like most pseudogenes, HMGN2P19 is considered a relic of gene duplication and evolutionary processes and does not encode an active protein or serve a direct biological function[2][4][5]. While some pseudogenes are transcribed and may rarely act through noncoding RNA species to regulate gene expression, there is no evidence that HMGN2P19 fulfills any known regulatory or disease-associated role in humans. Therefore, it is not a drug target and has no therapeutic, biomarker, or safety relevance[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group nucleosomal binding domain 2 pseudogene 19 (HMGN2P19).